← boardnext 2028-06
SLNO
Soleno Therapeutics, Inc.distress 0/10 · well-funded / low risk$53.010%today-40% from 52w high
Lead: Prader-Willi Syndrome
Revenue
pre-revenue
Liquidity
$529M
Runway
—
Shares 1y
—
Price & events
+21.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.1%
1W
+0.4%
1M
+37.3%
3M
+9.2%
6M
-29.3%
1Y
—
2Y
—
5Y
+16.0%
All
Overview
- Volume
- 0
- 52 Week Range
- $30.05 – $88.49
- Float Shares
- 51.46M
- Short %
- 17.89%
- % Held by Insiders
- 1.31%
- % Held by Institutions
- 111.53%
- Beta
- -2.22
Pipeline stages · 1 programs
DCCR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-06 Estimated 50% readout ~2028-08-15 | Phase 3 | DCCR | Prader-Willi Syndrome | — | active not recruiting |
Catalyst news & presentations · 1
- 2026-08-05earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $53 (0% upside) · 5 analysts
- 2026-04-17Wells FargoOverweight → Equal-Weight
- 2026-04-08HC Wainwright & Co.Buy → Neutral
- 2026-04-07TD CowenBuy → Hold
- 2026-04-07Wolfe ResearchOutperform → Peer Perform
- 2026-04-06Cantor FitzgeraldOverweight → Neutral
- 2026-03-18OppenheimerOutperform
Competitors — Prader-Willi Syndrome
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- HRMYHarmony Biosciences Holdings, Inc.$2.0B · D0
- RLMDRELMADA THERAPEUTICS, INC.$511M · D6
- DRUGBRIGHT MINDS BIOSCIENCES INC.$331M · D2
- TNXPTonix Pharmaceuticals Holding Corp.$170M · D7
- AARDAardvark Therapeutics, Inc.$142M · D5
- PTNPALATIN TECHNOLOGIES INC$14M · D9
Recent news
- 2026-07-21Trading Systems Reacting to (SLNO) Volatility - Stock Traders Daily
- 2026-07-20Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
- 2026-07-17Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therapeutics, Inc. (SLNO) And Encourages Shareholders to Connect - ACCESS Newswire
- 2026-07-13Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Navigating A Stable Path In Biotechnology - DirectorsTalk Interviews
- 2026-07-08Soleno Therapeutics (SLNO) Cantor Global Healthcare Conference 2025 Summary - Quartr
- 2026-07-07Soleno Therapeutics (SLNO) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
- 2026-07-06Soleno Therapeutics (SLNO) Jefferies London Healthcare Conference 2024 Summary - Quartr
- 2026-06-15Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.